Navigation Links
Pharmacyclics Reports Second Quarter 2014 Results
Date:7/31/2014

e opinion was based on data from the Phase II study (PCYC-1104) in MCL, a Phase III RESONATE™ study (PCYC-1112-CA) and a Phase II study (PCYC-1102) in CLL.

The EMA is a decentralized agency of the European Union responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the 28 countries of the European Union. The positive opinion of the EMA's CHMP will be reviewed by the European Commission, and a final decision on IMBRUVICA is anticipated later this year. In addition to European markets, a worldwide regulatory filing program for IMBRUVICA currently is underway.

Clinical UpdateIMBRUVICA (ibrutinib) clinical trials are active in all regions including US, Europe, Asia Pacific, Canada and Latin America. Currently IMBRUVICA is being developed in 8 different B-cell malignancies. There are 12 Phase III clinical trials initiated with IMBRUVICA and a total of 50 trials are registered on www.clinicaltrials.gov, of which 23 are investigating combination regimens while the remaining 27 are investigating IMBRUVICA monotherapy. The total planned enrollment for all of our clinical studies investigating IMBRUVICA is approximately 7,200 patients. As of today there are seven Phase III studies focused on patients with CLL, two designed for patients with MCL, one for patients with diffuse large B-cell lymphoma, one for patients with follicular lymphoma and one for Waldenstroms macroglobulinemia. To date, over 3,300 patients have been treated in Company-sponsored trials which are being conducted in over 35 countries around the globe and which involve more than 800 principal investigators.

During the second quarter, we initiated a Company-sponsored, randomized, double-blind, placebo-controlled, Phase III study of IMBRUVICA or placebo in combination with rituximab in previously treated Waldenstrom's Macroglobulinemia patients. The total planned enrollment for this study i
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014
2. Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
3. WuXi PharmaTech to Partner with Pharmacyclics
4. Pharmacyclics Reports Third Quarter 2013 Results
5. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
6. Pharmacyclics Reports Second Quarter 2013 Results
7. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
8. Pharmacyclics Reports First Quarter 2013 Results
9. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
10. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
11. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company ... on the Mylan N.V. ("Mylan") (NASDAQ: MYL ) ... Perrigo. "Our views of Mylan,s offer to ... be, based on our Board,s careful reflection of the ... on the limited choices that Mylan has allowed its ...
(Date:8/28/2015)... and ATLANTA , August 28, 2015 ... Food and Drug Administration (FDA) cleared the MagVita TMS Therapy ... patients who have failed to receive satisfactory improvement from prior ... technique for stimulating neural tissue in the part of the ... procedure has been proven safe and effective and MagVenture is ...
(Date:8/28/2015)... South Korea , Aug. 28, 2015 ... National University and Dr. Ra from Biostar , ... , Confirmed 30% increase of lifespan through multiple IV ... function, physical vitality, and life expectancy found , ... in Korea have determined the possibility that adult mesenchymal ...
Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2
(Date:8/29/2015)... ... August 30, 2015 , ... On September 30, 2015, the Career ... the 10 regionally accredited Maricopa Community Colleges , will be hosting a Job ... pursuing employment information and opportunities. , The Expo has expanded to much more than ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made possible by ... of patients, according to a newly published report. Surviving Mesothelioma has more on ... , The authors of the new paper focus on several types of ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... chronic obstructive pulmonary disease (including emphysema), or asthma, are at higher risk from ... previous heart attack, heart failure or heart-rhythm problems (arrhythmia or irregular heartbeat) are ...
(Date:8/28/2015)... ... 28, 2015 , ... Joining a growing number of hospitals ... management companies to partner with Wound Care Advantage (WCA) to utilize the ... , Transitioning wound care management providers can be a complex undertaking. WCA provides ...
(Date:8/28/2015)... ... August 28, 2015 , ... With the goal of ... for the second year to the Adams County Fairgrounds in Mendon, IL on May ... raise money to support music education in the underfunded school districts of Mendon and ...
Breaking Medicine News(10 mins):Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2
... contain possibly hazardous chemicals called polybrominated diphenyl ethers (PBDEs). ... Standards and Technology and the Environmental Protection Agency of ... yet clear how dangerous these PBDEs are, though some ... structure is strikingly similar to that of PCBs, which ...
... are suffering from mental illness after serving in war-torn ... or longer for treatment// from the National Health Service ... by British Ministry of Defence (MoD) showed 2,123 servicemen ... after returning from Iraq since 2003. More than 320 ...
... has set up a facility in Chennai, the state ... ,Called Poison Control Training and Research Centre, ... It can handle emergency situations like mass poisoning. It ... services and counseling. An intensive care unit, a library, ...
... the hospitals run by NHS trusts, more and more people ... According to the Daily Telegraph, the bed occupancy rates in ... ,Norman Lamb, the health spokesman of the Liberal ... an uphill task to keep patients clean and isolate them. ...
... a tool to help hospitals prepare for disasters ... Electronic Mass Casualty Assessment & Planning Scenarios (EMCAPS) ... as a flu epidemic, bioterrorist attack, flood or ... of victims, wind direction, available medical resources, bacterial ...
... posed by mercury contaminated fish are enormous and especially ... careful about how much// and which fish they eat ... a special issue of the international science journal Ambio. ... Mercury as a Global Pollutant last August in Madison, ...
Cached Medicine News:Health News:Methylmercury in Marine Fish Pose Health Risks to Pregnant Women and Elderly Men 2Health News:Methylmercury in Marine Fish Pose Health Risks to Pregnant Women and Elderly Men 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: